HUANG MICHAEL F. (Sr. VP of Clinical Development) sold 14.2% of their position (6.58K shares) of SOLENO THERAPEUTICS INC on the open market
Open‑market sale worth $200.4K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 3/31/2026ACC: 0002019992-26-000002
Officer· Sr. VP of Clinical Development
Since Apr 2024
-6.58K
Net shares
Net seller
$200.4K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
6.58K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−4.26K
Price / share
$30.04
Trade value
$127.84K
% of position
9.2%
3/27/2026
46.41K→42.15K
Common Stock
Direct
Shares
−1.84K
Price / share
$31.04
Trade value
$57.05K
% of position
4.4%
3/27/2026
42.15K→40.31K
Common Stock
Direct
Shares
−488.00
Price / share
$31.72
Trade value
$15.48K
% of position
1.2%
3/27/2026
40.31K→39.82K
Total
Net shares
−6.58K
Net value
-$200.36K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/27/2026 | S · Sale | −4.26K | $30.04 | $127.84K | 9.2% | 46.41K | 42.15K |
| Common Stock Direct | 3/27/2026 | S · Sale | −1.84K | $31.04 | $57.05K | 4.4% | 42.15K | 40.31K |
| Common Stock Direct | 3/27/2026 | S · Sale | −488.00 | $31.72 | $15.48K | 1.2% | 40.31K | 39.82K |
| Total | −6.58K | -$200.36K | ||||||
Derivative Transactions0
No derivative transactions reported